TY - JOUR
T1 - Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer
T2 - the Lucerne toolbox
AU - Dubsky, Peter
AU - Pinker, Katja
AU - Cardoso, Fatima
AU - Montagna, Giacomo
AU - Ritter, Mathilde
AU - Denkert, Carsten
AU - Rubio, Isabel T.
AU - de Azambuja, Evandro
AU - Curigliano, Giuseppe
AU - Gentilini, Oreste
AU - Gnant, Michael
AU - Günthert, Andreas
AU - Hauser, Nik
AU - Heil, Joerg
AU - Knauer, Michael
AU - Knotek-Roggenbauerc, Mona
AU - Knox, Susan
AU - Kovacs, Tibor
AU - Kuerer, Henry M.
AU - Loibl, Sibylle
AU - Mannhart, Meinrad
AU - Meattini, Icro
AU - Penault-Llorca, Frederique
AU - Radosevic-Robin, Nina
AU - Sager, Patrizia
AU - Španić, Tanja
AU - Steyerova, Petra
AU - Tausch, Christoph
AU - Peeters, Marie Jeanne T.F.D.Vrancken
AU - Weber, Walter P.
AU - Cardoso, Maria J.
AU - Poortmans, Philip
N1 - Funding Information:
Complete funding and organisational support of the consensus meeting was provided by Hirslanden Klinik St Anna (Lucerne, Switzerland). The funding source had no role in the study design, in the collection, analysis, and interpretation of data, in the writing of the report, and in the decision to submit this Policy Review for publication. The panel would like to thank Judith Eberhard for her online secretarial work and organising the face-to-face consensus meeting in Lucerne. Rebecca Bellerby (w2o group) provided essential guidance in writing and discussing strengths, weaknesses, and conformity with other guideline work. Joanne Chin provided editorial assistance during the preparation of this Policy Review. This work was endorsed and supported by ESSO, ESTRO, EUSOBI, EUSOMA, ESO, ESMO, EUROPA DONNA, OPBC, and NHBCC, and during the writing stage by EUBREAST.
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/1
Y1 - 2021/1
N2 - Primary systemic therapy is increasingly used in the treatment of patients with early-stage breast cancer, but few guidelines specifically address optimal locoregional therapies. Therefore, we established an international consortium to discuss clinical evidence and to provide expert advice on technical management of patients with early-stage breast cancer. The steering committee prepared six working packages to address all major clinical questions from diagnosis to surgery. During a consensus meeting that included members from European scientific oncology societies, clinical trial groups, and patient advocates, statements were discussed and voted on. A consensus was reached in 42% of statements, a majority in 38%, and no decision in 21%. Based on these findings, the panel developed clinical guidance recommendations and a toolbox to overcome many clinical and technical requirements associated with the diagnosis, response assessment, surgical planning, and surgery of patients with early-stage breast cancer. This guidance could convince clinicians and patients of the major clinical advancements purported by primary systemic therapy, the use of less extensive and more targeted surgery to improve the lives of patients with breast cancer.
AB - Primary systemic therapy is increasingly used in the treatment of patients with early-stage breast cancer, but few guidelines specifically address optimal locoregional therapies. Therefore, we established an international consortium to discuss clinical evidence and to provide expert advice on technical management of patients with early-stage breast cancer. The steering committee prepared six working packages to address all major clinical questions from diagnosis to surgery. During a consensus meeting that included members from European scientific oncology societies, clinical trial groups, and patient advocates, statements were discussed and voted on. A consensus was reached in 42% of statements, a majority in 38%, and no decision in 21%. Based on these findings, the panel developed clinical guidance recommendations and a toolbox to overcome many clinical and technical requirements associated with the diagnosis, response assessment, surgical planning, and surgery of patients with early-stage breast cancer. This guidance could convince clinicians and patients of the major clinical advancements purported by primary systemic therapy, the use of less extensive and more targeted surgery to improve the lives of patients with breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=85098485045&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098485045&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(20)30580-5
DO - 10.1016/S1470-2045(20)30580-5
M3 - Review article
C2 - 33387500
AN - SCOPUS:85098485045
SN - 1470-2045
VL - 22
SP - e18-e28
JO - The lancet oncology
JF - The lancet oncology
IS - 1
ER -